Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas

  • Ugwuji N. Maduekwe
  • Francis J. Hornicek
  • Dempsey S. Springfield
  • Kevin A. Raskin
  • David C. Harmon
  • Edwin Choy
  • Andrew E. Rosenberg
  • G. Petur Nielsen
  • Thomas F. DeLaney
  • Yen-Lin Chen
  • Mark J. Ott
  • Sam S. Yoon
Bone and Soft Tissue Sarcomas



Soft tissue sarcomas generally have a ≤5% risk of lymph node metastasis, but synovial, epithelioid, and clear cell subtypes reportedly have a much higher risk. The utility of sentinel lymph node biopsy (SLNB) for patients with these sarcoma subtypes is unknown.


29 patients with nonmetastatic synovial, epithelioid, and clear cell sarcomas who underwent SLNB were examined.


Median age was 35 years (range 11–73 years), and 69% were male. Tumors were located in the lower extremity in 17 patients and the upper extremity in 12. The histological subtypes were synovial sarcoma in 16 patients, epithelioid sarcoma in 10, and clear cell sarcoma in 3. All patients had a staging chest computed tomography (CT) scan, none of which were suspicious, and 20 patients had staging positron emission tomography (PET) scans (16 negative, 3 indeterminate, and 1 suspicious). All patients had resection of their primary tumor. At least one sentinel node was found in 28 patients (97%), and the median number of sentinel nodes identified was 2 (range 1–4). One patient had a positive sentinel node on routine hematoxylin and eosin (H&E) staining and developed lung metastases. Two patients had positive sentinel nodes following immunohistochemical staining, and both remain disease free despite not undergoing completion lymphadenectomy. One patient developed a lymph node metastasis after a negative SLNB.


For patients with these sarcoma subtypes without radiological evidence of nodal or distant metastases, the incidence of occult lymph node metastasis is relatively low. Determining utility of SLNB may require a multicenter trial.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Behranwala KA, A’Hern R, Omar AM, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol. 2004;11:714–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Riad S, Griffin AM, Liberman B, Blackstein ME, Catton CN, Kandel RA, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004;426:129–34.Google Scholar
  5. 5.
    Wagner W, Willich N, Rube C, Prott FJ, Micke O. [Treatment results of soft tissue sarcomas in adults]. Strahlenther Onkol. 1994;170:91–9.PubMedGoogle Scholar
  6. 6.
    Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60:1800–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB. Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer. 1999;86:969–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Daigeler A, Kuhnen C, Moritz R, Stricker I, Goertz O, Tilkorn D, et al. Lymph node metastases in soft tissue sarcomas-a single center analysis of 1,597 patients. Langenbecks Arch Surg. 2008;394:321–9.Google Scholar
  9. 9.
    Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339:941–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–8; discussion 468–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedGoogle Scholar
  12. 12.
    Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759–67.PubMedCrossRefGoogle Scholar
  13. 13.
    Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. 2003;238:538–49; discussion 549–50.PubMedGoogle Scholar
  15. 15.
    Leong SP, Kashani-Sabet M, Desmond RA, Kim RP, Nguyen DH, Iwanaga K, et al. Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg. 2005;29:683–91.PubMedCrossRefGoogle Scholar
  16. 16.
    Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, et al. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2007;14:3542–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Blazer DGr, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol. 2003;12:201–6.PubMedCrossRefGoogle Scholar
  18. 18.
    de Visscher SA, van Ginkel RJ, Wobbes T, Veth RP, Ten Heuvel SE, Suurmeijer AJ, et al. Epithelioid sarcoma: Still an only surgically curable disease. Cancer. 2006;107:606–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence—SEER 17 Regs Limited-Use, Nov 2006 Sub (1973–2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission [accessed March 2008].
  20. 20.
    Greene FL PDL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag, 2002.Google Scholar
  21. 21.
    Tunn PU, Andreou D, Illing H, Fleige B, Dresel S, Schlag PM. Sentinel node biopsy in synovial sarcoma. Eur J Surg Oncol. 2008;34:704–7.Google Scholar
  22. 22.
    Al-Refaie WB, Ali MW, Chu DZ, Paz IB, Blair SL. Clear cell sarcoma in the era of sentinel lymph node mapping. J Surg Oncol. 2004;87:126–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Fantini F, Monari P, Bassissi S, Maiorana A, Cesinaro AM. Sentinel lymph node biopsy in clear cell sarcoma. J Eur Acad Dermatol Venereol. 2007;21:1271–2.PubMedGoogle Scholar
  24. 24.
    Picciotto F, Zaccagna A, Derosa G, Pisacane A, Puiatti P, Colombo E, et al. Clear cell sarcoma (malignant melanoma of soft parts) and sentinel lymph node biopsy. Eur J Dermatol. 2005;15:46–8.PubMedGoogle Scholar
  25. 25.
    van Akkooi AC, Verhoef C, van Geel AN, Kliffen M, Eggermont AM, de Wilt JH. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol. 2006;32:996–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Seal A, Tse R, Wehrli B, Hammond A, Temple CL. Sentinel node biopsy as an adjunct to limb salvage surgery for epithelioid sarcoma of the hand. World J Surg Oncol. 2005;3:41.PubMedCrossRefGoogle Scholar
  27. 27.
    Cochran AJ, Ohsie SJ, Binder SW. Pathobiology of the sentinel node. Curr Opin Oncol. 2008;20:190–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 1994;7:502–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman F, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4:341–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:S97–102.PubMedCrossRefGoogle Scholar
  31. 31.
    Acland KM, Healy C, Calonje E, O’Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–8.PubMedGoogle Scholar
  32. 32.
    Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Chagpar AB, Carlson DJ, Laidley AL, et al. Factors influencing the number of sentinel lymph nodes identified in patients with breast cancer. Am J Surg. 2007;194:860–4; discussion 864–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Lin KM, Patel TH, Ray A, et al. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg. 2004;199:561–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Mudun A, Sanli Y, Ozmen V, et al. Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer: single institution experience. Clin Nucl Med. 2008;33:262–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Karam A, Stempel M, Cody HSr, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg. 2008;207:543–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Port ER, Fey J, Gemignani ML, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg. 2002;195:167–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Roumen RM, Kuijt GP, Liem IH. Lymphatic mapping and sentinel node harvesting in patients with recurrent breast cancer. Eur J Surg Oncol. 2006;32:1076–81.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Ugwuji N. Maduekwe
    • 1
  • Francis J. Hornicek
    • 2
  • Dempsey S. Springfield
    • 2
  • Kevin A. Raskin
    • 2
  • David C. Harmon
    • 3
  • Edwin Choy
    • 3
  • Andrew E. Rosenberg
    • 4
  • G. Petur Nielsen
    • 4
  • Thomas F. DeLaney
    • 5
  • Yen-Lin Chen
    • 5
  • Mark J. Ott
    • 6
  • Sam S. Yoon
    • 1
  1. 1.Division of Surgical Oncology, Department of SurgeryMassachusetts General HospitalBostonUSA
  2. 2.Division of Orthopedic Oncology, Department of OrthopedicsMassachusetts General HospitalBostonUSA
  3. 3.Division of Hematology/Oncology, Department of MedicineMassachusetts General HospitalBostonUSA
  4. 4.Department of PathologyMassachusetts General HospitalBostonUSA
  5. 5.Department of Radiation OncologyMassachusetts General HospitalBostonUSA
  6. 6.Department of SurgeryLDS HospitalSalt Lake CityUSA

Personalised recommendations